Overview

Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of RG1068 (synthetic human secretin) with MRCP in subjects with abnormalities of the pancreas.
Phase:
Phase 3
Details
Lead Sponsor:
Repligen Corporation
Treatments:
Secretin